This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Boston Scientific (BSX) Buys Lumenis to Expand in Urology
by Zacks Equity Research
The transaction is expected to remain immaterial to Boston Scientific's (BSX) 2021 adjusted earnings per share.
Abbott (ABT) Gets Canadian Nod for FreeStyle Libre Expanded Use
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre is the only glucose sensing technology available in Canada to remotely monitor glucose status in an expectant mother to reduce exposure to COVID-19.
Omnicell (OMCL) Grows on New Services Amid Pandemic Woes
by Zacks Equity Research
Omnicell (OMCL) is progressing in autonomous pharmacy space by expanding portfolio and investing in the digital cloud-based platform.
Medtronic's (MDT) Market Share Grows Amid COVID-19 Woes
by Zacks Equity Research
In Coronary, the ongoing issue related to the China drug-eluting stent national tender, Medtronic (MDT) is currently winning share globally.
Thermo Fisher (TMO) Buys Mesa Biotech, Grows in Point of Care
by Zacks Equity Research
Mesa Biotech's point-of-care platform is likely to help Thermo Fisher (TMO) rapidly scale up manufacturing volume amid the pandemic.
NuVasive (NUVA) Boosts Cervical Portfolio With New Buyout
by Zacks Equity Research
NuVasive (NUVA) expands comprehensive portfolio of C360 with the addition of Simplify Disc.
Envista (NVST) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of 40.00% and 10.75%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Envista (NVST) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Envista (NVST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Value Investors Choose Envista Holdings (NVST) Stock Now?
by Zacks Equity Research
Is Envista Holdings (NVST) a great pick from the value investor's perspective right now? Read on to know more.
Can Value Investors Choose Envista Holdings (NVST) Stock Now?
by Zacks Equity Research
Is Envista Holdings (NVST) a great pick from the value investor's perspective right now? Read on to know more.
Envista (NVST) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of 433.33% and 25.79%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Envista (NVST) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Envista (NVST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Surprise Coming for Envista Holdings (NVST) This Earnings Season?
by Zacks Equity Research
Envista Holdings (NVST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why the Earnings Surprise Streak Could Continue for Envista (NVST)
by Zacks Equity Research
Envista (NVST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cardinal Health (CAH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter performance is likely to reflect solid performance in Pharmaceutical segment.
3 Medical Product Stocks Set to Beat This Earnings Season
by Trina Mukherjee
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on several factors.
New Strong Sell Stocks for April 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
NVST vs. GNNDY: Which Stock Is the Better Value Option?
by Zacks Equity Research
NVST vs. GNNDY: Which Stock Is the Better Value Option?
Danaher to Lower Stake in Envista, Finalizes Exchange Ratio
by Zacks Equity Research
Danaher (DHR) sets the exchange ratio for each share of Danaher common stock at 5.5784 shares of Envista common stock.
Danaher (DHR) Beats Q3 Earnings Estimates, Lowers '19 View
by Zacks Equity Research
Danaher's (DHR) third-quarter 2019 earnings benefit from organic sales growth, acquisitions and DBS initiatives. It lowers 2019 projection, accounting for the Envista transaction.